Citi raised the firm’s price target on Regeneron (REGN) to $900 from $700 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron double upgraded to Buy at BofA on more bullish Eylea HD view
- Regeneron upgraded to Buy from Underperform at BofA
- Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria
- Regeneron Advances Phase 3 Antibody Trial in Birch Pollen Eye Allergy: What Investors Should Know
- Regeneron, Sanofi get marketing authorization for Dupixent from MHLW in Japan